21/10/2026 KEYTRUDA + Padcev receives EC approval for perioperative treatment of resectable MIBC US FDA grants Fast Track designation to Samsung Bioepis' SBE303 ADC for post-enfortumab vedotin advanced urothelial cancer Onvansertib has been granted the US FDA Orphan Drug Designation for Chronic Myelomonocytic Leukemia KEYTRUDA + Padcev receives EC approval for perioperative treatment of resectable MIBC (Ref) Merck & Co./MSD announced that the European Commission approved KEYT

27/05/2026 FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials (Ref) Solu Therapeutics’ investigational therapy STX-0712 has received Fast Track designation for relapsed/refractory chronic myelomonocytic leukemia (CMML) Ongoing Trials - A Phase 1, open-label, multicenter tria